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Abstract Spinal cord injury (SCI) is a devastating condition
of the central nervous system (CNS) often resulting in severe
functional impairment and for which there are not yet restor-
ative therapies. In the present study, we performed a widely
used model of SCI to determine the neuroprotective propriety
of palmitoylethanolamide (PEA) and the antioxidant effect of
a flavonoid luteolin (Lut), given as a co-ultramicronized com-
pound co-ultraPEALut. In particular, by western blot analysis
and immunofluorescence staining, we investigated whether
this compound (at the dose of 1 mg/kg) was able to modulate
autophagy. Our results showed that treatment with co-
ultraPEALut after SCI reduced the expression of proteins pro-
moter of autophagy such as Beclin-1 and microtubule-
associated protein 1A/1B-light chain 3 (MAP-LC3). In con-
trast, this compound decreased the levels of mammalian target
of rapamycin (mTOR), p-Akt, and p-70S6K which are pro-
teins that inhibit autophagy. These data confirmed that the
protective role of co-ultraPEALut is associated with inhibition
of excessive autophagy and regulation of protein degradation.
Therefore, treatment with co-ultraPEALut could be consid-
ered as a possible therapeutic approach in an acute traumatic
lesion like SCI.
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Introduction
Spinal cord injury (SCI) is defined as an acute traumatic lesion
of neural elements in the spinal canal (spinal cord and cauda
equina), resulting in a change, either temporary or permanent,
in normal motor, sensory, or autonomic function. Spinal cord
injury usually begins with a sudden, traumatic blow to the
spine that causes local segmental damage to the spinal cord,
which is called primary injury [1, 2]. The primary damage to
the tissue is followed by a second phase of tissue degenera-
tion, the secondary injury that can occur over weeks or even
months. In secondary injury, acute inflammation can develop
into a chronic process if feedback mechanisms fail to inhibit
amplification of the inflammatory response. Chronic inflam-
mation leads to a continuous influx of neutrophils, macro-
phages, lymphocytes, and eosinophils from the circulation,
causing more destruction and scarring of tissue [3]. Cell death
resulting from all of these mechanisms occurs through necrot-
ic and apoptotic phenomena or autophagy.
Concern about autophagy has recently increased because
of its potential role in neurodegenerative diseases, such as
Parkinson’s and Alzheimer’s diseases, where autophagy may
be a protective mechanism [4]. Earlier studies also demon-
strated increased autophagic activity at lesion sites after cere-
bral hypoxia-ischemia (HI) injury [5], intracerebral hemor-
rhage (ICH) [6], and traumatic brain injury (TBI) [7, 8].
Autophagy, literally Bself-eating, is now recognized as an
intracellular catabolic mechanism for the degradation, elimi-
nation, and recycling of long-lived proteins and unwanted
organelles in a cell during development and under stress con-
ditions [9, 10]. Therefore, autophagy plays an important role
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in homeostasis and also to a kind of cell death, which is known
as autophagic cell death [11, 12]. It begins with the formation
of double-membraned vesicle that subsequently engulfs cyto-
plasmic components, including cytosolic proteins and organ-
elles, to become autophagosomes (APs). APs fuse with lyso-
somes to form autolysosomes, and intra-autophagosomal
components are degraded by lysosomal hydrolases. Several
key molecular components participate in the initiation, pro-
gression, and completion of autophagy, like the mammalian
target of rapamycin (mTOR) that inhibits autophagy, whereas
Beclin 1 and LC3 promote it [8, 13]. However, autophagy
seems to be a double-edged sword that protects cells when it
is moderately activated, yet its excessive activation can induce
autophagic cell death [14].
In recent years, the pathophysiology of SCI has been a
focus of extensive studies; animal models have been proved
to be important tools in this field and are employed to inves-
tigate the mechanisms of primary and secondary injury. Pre-
vious studies have shown that autophagy plays a key role in
secondary injury in both animal models and human tissue by
causing progressive degeneration of the spinal cord [15, 16].
However, the molecular pathway of secondary injury and the
role of autophagy in the recovery of SCI remain unclear. Fol-
lowing acute spinal cord injury, an increase in mTOR expres-
sion and p70S6K activity also may be required for functional
improvement [17]. The involvement of autophagic mecha-
nism underlying spinal neuroprotective effects of
palmitoylethanolamide (PEA) and luteolin association was
never been investigated. Thus, we studied the autophagic
pathway involved in spinal cord compression and to explore
the effects of the treatment with a new co-ultramicronized
composite of N-PEA and luteolin (Lut) on autophagy expres-
sion. This formulation (co-ultraPEALut) is based on associa-
tion of anti-inflammatory PEAwith anti-oxidant Lut on a 10:1
mass basis. We have previously demonstrated that treatment
with co-ultraPEALut significantly reduced the inflammatory
process in an ex vivo model of spinal cord organotypic cul-
tures and in experimental mouse models of TBI [18, 7]. Fur-
thermore in this last model, we showed that co-ultraPEALut
reduced autophagy after TBI [7].
Therefore, the aim of this study was to demonstrate that




CD1 mice (male 25–30 g; Harlan Nossan, Milan, Italy) were
housed in a controlled environment and provided with stan-
dard rodent chow and water. Mice were housed in stainless
steel cages in a room kept at 22±1 °C with a 12-h light, 12-h
dark cycle. The animals were acclimatized to their environ-
ment for 1 week and had ad libitum access to tap water and
rodent standard diet. The study was approved by the Univer-
sity of Messina Review Board for the care of animals. All
animal experiments complied with regulations in Italy (D.M.
116192) as well as the EU regulations (O.J. of E.C. L 358/1
12/18/1986).
Co-ultramicronization Process of PEA and Lut
The co-ultramicronization process was performed using jet
mill equipment (Sturtevant, Inc., 348 Circuit Street Hanover,
MA, USA) with a chamber of 300 mm in diameter, operated
with Bspiral technology^ and driven by compressed air at 10
to 12 bars. Crashing was determined by the high number of
collisions that occurred among particles as a result of the high
level of kinetic (not mechanical) energy. This process is effec-
tive not only in reducing product particle size but also in
modifying crystalline structure. Scanning electronmicroscopy
showed an intimate intermixing of PEA and Lut, while anal-
ysis by differential scanning calorimetry and X-ray diffraction
indicated transformation into a crystalline form different from
the original two, definable as Ba higher energy content form.^
The composite showed the following particle size distribution:
96 % <10 μm, 80 % <5 μm, and 40 % <2 μm. Co-
ultraPEALut (Epitech Group s.r.l.) was dissolved in 10 % eth-
anol (Sigma-Aldrich, St Louis, MO, USA) and used at a con-
centration of 1 mg/kg in the in vivo study.
The dose of co-ultraPEALut (1 mg/kg) used was based on
previous in vivo studies [18].
SCI
Mice were anesthetized with intraperitoneal administration of
ketamine and xylazine (2.6 and 0.16 mg/kg body weight, re-
spectively). A longitudinal incision was made on the midline
of the back, exposing the paravertebral muscles, as previously
described [18]. These muscles were dissected away, the spinal
cord was exposed via a four-level T5 to T8 laminectomy, and
SCI was produced by extradural compression at T6 to T7
level, using an aneurysm clip with a closing force of 24 g.
Following surgery, 1.0 cm3 of saline was administered subcu-
taneously in order to replace the blood volume lost during the
surgery. During recovery from anesthesia, mice were placed
on a warm heating pad and covered with a warm towel. The
mice were individually housed in a temperature-controlled
room at 27 °C. Food and water were provided to the mice
ad libitum. During this time period, the animals’ bladders
were manually voided twice a day until the mice were able
to regain normal bladder function. In all injured groups, the
spinal cord was compressed for 1 min. Sham animals were
only subjected to laminectomy. Spinal cord tissues were taken
at 24 h after trauma. Tissue segments contained the lesion
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(1 cm on each side of the lesion), according to counts of
retrogradely labeled neurons at the origin of distinct descend-
ing motor pathways and to morphometric assessments of nor-
mal residual tissue at the injury epicenter, as previously de-
scribed [19].
Experimental Groups and Treatments
Mice Were Randomly Allocated into the Following Groups
1. Sham+vehicle: mice were subjected to laminectomy, but
the aneurysm clip was not applied and treated intraperito-
neally (i.p.) with vehicle (n=30).
2. Sham+co-ultraPEALut (10:1)=same as the Sham+vehi-
cle group, but co-ultraPEALut was administered at the
final dose of 1 mg/kg i.p. at 1 and 6 h after laminectomy
(n=30).
3. SCI+vehicle: mice were subjected to laminectomy and
the aneurysm clip was applied (n=30).
4. SCI+co-ultraPEALut (10:1): mice were subjected to SCI
and administered co-ultraPEALut at the final dose of
1 mg/kg i.p. at 1 and 6 h after SCI (n=30).
Western Blot Analysis
Cytosolic and nuclear extracts were prepared with slight mod-
ifications of a published procedure [20]. Spinal cord tissue
from each mouse was suspended in extraction Buffer A con-
taining 0.2 mM PMSF, 0.15 mM pepstatin A, 20 mM
leupeptin, 1 mM sodium orthovanadate, homogenized at the
highest setting for 2 min, and centrifuged at 12,000 rpm for
4 min at 4 °C. Supernatants represented the cytosolic fraction.
The pellets, containing enriched nuclei, were resuspended in
Buffer B containing 1% Triton X-100, 150 mMNaCl, 10mM
Tris–HCl pH 7.4, 1 mMEGTA, 1 mMEDTA, 0.2 mM PMSF,
20 mm leupeptin, and 0.2 mM sodium orthovanadate. After
centrifugation 10 min at 12,000 rpm at 4 °C, the supernatants
that we obtainedwere the nuclear proteins. Protein concentrations
were estimated by the Bio-Rad protein assay using bovine serum
albumin as standard. Briefly, samples were heated to 100 °C
for 5 min, and equal amounts of protein were separated on
18 % SDS-PAGE gel and transferred to nitrocellulose mem-
brane. Specific primary antibody, anti- anti-MAPLC3α
(1:500, Santa Cruz Biotechnology), Beclin-1 (1:500; Santa
Cruz Biotechnology), anti-p62 (1:1000; Cell Signaling),
anti-mTOR (1:1000; Cell Signaling), anti-p70S6K (1:1000;
Cell Signaling), and p-Akt (1:1000; Cell Signaling) were
mixed in 1× PBS, 5 % w/v nonfat dried milk, 0.1 % Tween-
20 (PMT), and incubated at 4 °C, overnight. After, mem-
branes were incubated with peroxidase-conjugated bovine
anti-mouse IgG secondary antibody or peroxidase-
conjugated goat anti-rabbit IgG (1:2000, Jackson
ImmunoResearch) for 1 h at room temperature. To ascertain
that blots were loaded with equal amounts of protein lysates,
they were also incubated in the presence of the antibody
against β-actin (1:5000; Santa Cruz Biotechnology). Signals
were detected with enhanced chemiluminescence detection
system reagent according to manufacturer’s instructions
(SuperSignal West Pico Chemiluminescent Substrate, Pierce).
The relative expression of the protein bands was quantified by
densitometry with Bio-Rad ChemiDoc™ XRS+software and
standardized to β-actin levels. Images of blot signals (8-bit/
600-dpi resolution) were imported to analysis software (Image
Quant TL, v2003). A preparation of commercially available
molecular weight markers made of proteins of molecular
weight 10 to 250 kDa was used to define molecular weight
positions and as reference concentrations for each molecular
weight.
Immunofluorescence Staining
After deparaffinization and rehydration, detection of GFAP,
NeuN, Beclin-1, andMAPLC3-αwas carried out after boiling
in 0.1 M citrate buffer for 1 min. Nonspecific adsorption was
minimized by incubating the section in 2 % (v/v) normal goat
serum in PBS for 20min. Sections were incubated withmouse
monoclonal anti-NeuN (1:100, v/v Millipore), or with mouse
monoclonal anti-GFAP (1:100, v/v Santa Cruz Biotechnolo-
gy), or with polyclonal rabbit anti-Beclin-1 (1:100, v/v Santa
Cruz, Biotechnology), or with rabbit anti-MAPLC3α (1:100,
v/v Santa Cruz Biotechnology) antibody in a humidified
chamber for O/N at 37 °C. Sections were washed with PBS
and were incubated with secondary antibody FITC-
conjugated anti-mouse Alexa Fluor-488 antibody (1:2000
v/v Molecular Probes, UK) and with TEXAS RED-
conjugated anti-rabbit Alexa Fluor-594 antibody (1:1000 in
PBS, v/v Molecular Probes, UK) for 1 h at 37 °C. Sections
were washed and for nuclear staining 4′,6′-diamidino-2-
phenylindole (DAPI; Hoechst, Frankfurt; Germany) 2 μg/ml
in PBS was added. Sections were observed and photographed
at ×20 magnification using a Leica DM2000 microscope
(Leica). All images were digitalized at a resolution of 8 bits
into an array of 2560×1920 pixels. Optical sections of fluores-
cence specimens were obtained using a HeNe laser (543 nm), a
laser UV (361–365 nm), and an argon laser (458 nm) at a 1-
min, 2-s scanning speedwith up to 8 averages; 1.5μm sections
were obtained using a pinhole of 250. Contrast and brightness
were established by examining the most brightly labeled pixels
and applying settings that allowed clear visualization of struc-
tural details while keeping the highest pixel intensities close to
200. The same settings were used for all images obtained from
the other samples that had been processed in parallel. Digital
images were cropped and figure montages prepared using
Adobe Photoshop CS5 (Adobe Systems; Palo Alto, CA).
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Light Microscopy
For histopathological examination by standard hematoxylin and
eosin (H&E) staining, the mice were anesthetized with ketamine
and xylazine (2.6 and 0.16 mg/kg body weight respectively)
24 h after injury and then perfused transcardially with cold
PBS (0.1 M). Tissues were removed under magnified vision,
and segments containing the lesion (1 cm on each side of the
lesion) were collected in 4 % paraformaldehyde for proper fix-
ation and then dehydrated with graded ethanol and embedded in
paraffin wax. Sections of 5-μm thickness were cut into longitu-
dinal sections for the posterior area of the spinal cord, stained
with H&E, and studied using light microscopy (Dialux 22
Leitz). Representative images were shown. Blinded histologic
scoring (Fig. 1d) was performed on a 6-point scale: 0, normal; 1,
1–5 eosinophilic neurons within the gray matter area; 2, 5–10
eosinophilic neurons; 3, >10 eosinophilic neurons; 4, a small
infarction (less than one-third of the gray matter area); 5, a mod-
erate infarction (one-third to one-half of the gray matter area);
and 6, a large infarction (more than half of the gray matter area).
Materials
Unless otherwise stated, all compounds were obtained from
Sigma-Aldrich, while co-ultraPEALut was a kind gift from
Epitech Group s.r.l. (Saccolongo, Italy). All other chemicals
were of the highest commercial grade available. All stock
solutions were prepared in non-pyrogenic saline (0.9 % NaCl,
Baxter, Milan, Italy) or 10 % dimethyl sulfoxide.
Statistical Evaluation
All values in the figures and the text are expressed as mean±
SEM. Results shown in the figures are representative of at
least three experiments performed on different in vivo exper-
imental days. In each experiment, we used five animals per
group, unless otherwise indicated. The results were analyzed
by one-way analysis of variance followed by a Bonferroni
post hoc test for multiple comparisons. A p value of less than
0.05 was considered significant.
Fig. 1 Effects of co-ultraPEALut treatment on histological alterations of
the spinal cord tissue 24 h after injury. Compared with the Sham-surgery
mice (a, a1), significant histologic damage to the spinal cord was evident
in mice subjected to SCI and treated with vehicle (b, b1). In the
perilesional area of the SCI mice, edema was evident, as and alteration
of the whitematter. A significant reduction of SCI-associated damagewas
observed in the tissue samples collected from mice treated with co-
ultraPEALut (c, c1). These data are also visible in the histological score
(d). ***p<0.001 vs Sham; ###p<0.001 vs SCI
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Results
Effect of Co-ultraPEALut on Histological Parameters
To evaluate the severity of the trauma at the level of the
perilesional area at 24 h after injury, the sections obtained
from each group were stained with hematoxylin and eosin
(H&E). Compared with the sham group (Fig. 1a, b, see mag-
nification higher a1 and b1, respectively), the SCI+vehicle
group showed the presence of edema and alteration of the
white matter (Fig. 1b, d, see magnification higher b1). Treat-
ment with co-ultraPEALut attenuated acute inflammation and
injury at 24 h after SCI (Fig. 1c, d, see magnification higher
c1).
Effect of Co-ultraPEALut on Autophagy After SCI:
Expression of Beclin-1, p62, and MAP-LC3
To investigate the mechanisms of autophagy after SCI, we
examined levels of proteins involved in the regulation and
formation of autophagosomes. Beclin-1 has a central role in
autophagy because it interacts with various cofactors inducing
autophagy. To compare the level of Beclin-1 protein between
the injured and the treated spinal cord section, western blot
analysis was performed. We showed that Beclin-1 expression
dramatically increased in the spinal cord tissue (T6 to T8 tract)
collected from mice subjected to SCI compared to the sham
group, while the treatment with co-ultraPEALut significantly
reduced SCI-induced Beclin-1 expression (Fig. 2a, see densi-
tometry analysis in a1). For more accurate quantification of
co-ultraPEALut effects on autophagy process, we examined
levels of p62 by western blot analysis. We detected that p62
expression increased after SCI, whereas the treatment with co-
ultraPEALut significantly reduced levels of this protein
(Fig. 2b, see densitometry analysis in b1). p62 also interacts
with a central component of the machine autophagy, autoph-
agic marker MAP-LC3, and carries the altered proteins to
degradation by autophagy. Therefore, by western blot analy-
sis, we showed that the ratio of LC3 I to LC3 II increased in
untreated animals 24 h after injury, though this ratio signifi-
cantly diminished to near sham levels of expression following
co-ultraPEALut treatment (Fig. 2c, see densitometry analysis
in c1), suggesting a reversal of autophagic activity upregula-
tion seen following SCI.
Fig. 2 Effect of co-ultraPEALut about proteins promoting autophagy
after SCI. Western blot analysis for Beclin-1, p62, and LC3 showed an
increase of levels of these proteins in SCI group compared to the Sham
group, whereas the treatment with co-ultraPEALut significantly reduced
SCI-induced Beclin-1, p62, and LC3 expression (a, a1; b, b1; c, c1
respectively). The data are representative of at least three independent
experiments. a **p<0.01 vs Sham; ##p<0.01 vs SCI. b **p<0.01 vs
Sham; #p<0.05 vs SCI. c *p<0.05 vs Sham; #p<0.05 vs SCI
Mol Neurobiol (2016) 53:3783–3792 3787
Effect of Co-ultraPEALut on Beclin-1 and MAP-LC3
Expression by Immunofluorescence Staining
To better understand the Beclin-1 and MAP-LC3 expression in
a specific population of cells, including neurons and astrocytes,
the spinal cord sections (T6 to T8 tract) at 24 h after compres-
sion were double-stained for Beclin-1 (red) or MAP-LC3 (red)
and various cell typemarkers, such as NeuN (green) for neurons
and GFAP (green) for astrocytes (Figs. 3 and 4). In the double
staining, the expression of Beclin-1 was observed in NeuN and
GFAP-labeled cells of the injured SCI group (Fig. 3g–i and j–l,
respectively) compared to Sham (Fig. 3a–c and d–f, respective-
ly), whereas a treatment with co-ultraPEALut not only de-
creased significantly these proteins expression but also the dou-
ble staining is less observed in both NeuN and GFAP (Fig. 3m–
o and p–r, respectively). Similarly, at 24 h after SCI, double
staining of LC3 revealed a strong co-localization with NeuN
and GFAP in SCI group (Fig. 4g–i and j–l, respectively) com-
pared to the Sham group (Fig. 4a–c and d–f, respectively), while
treatment of co-ultraPEALut decreased significantly these pro-
tein expressions (Fig. 4m-o and p-r respectively).
Effect of Co-ultraPEALut on PI3K/Akt/mTOR Pathway
After SCI
The PI3K/Akt/mTOR pathway is an intracellular signaling
pathway important in regulating the cell cycle. mTOR is
upstream signal in the regulation of autophagy which is pos-
itively regulated by PI3K/Akt and results in the inhibition of
autophagy. Therefore, by western blot analysis, we detected
the activity of Akt/mTOR signaling pathways in our model
in vivo. Our results showed that p-Akt and mTOR levels de-
creased significantly after SCI, compared with the Sham
group, while co-ultraPEALut treatment increased p-Akt and
mTOR expression, inhibiting autophagy (Fig. 5a, c, see den-
sitometry analysis in a1 and b1, respectively).
Moreover, a downstream target of mTOR signal a p70S6K
activity was assessed by western blot analysis. p70S6k activ-
ity was suppressed in mice after SCI, whereas the co-
ultraPEALut treatment enhanced activation of p70S6K signal-
ing (Fig. 5c, see densitometry analysis in c1).
Discussion
The CNS is sensitive to mechanical injuries causing perma-
nent functional deficits such as the case of patients who have
SCI. The mechanical forces imparted to the spinal cord cause
immediate tissue disruption, with direct axonal and neuronal
injury, inducing the death of neurons. Moreover, neurons con-
tinue to die for hours or days after SCI, as a consequence of
excitotoxicity, vascular dysfunction, and, in particular, be-
cause of the ensuing inflammatory response [21]. Inflamma-
tory responses are a major component of secondary injury and
Fig. 3 Co-localization of Neun/Beclin-1 and GFAP/Beclin-1 after SCI.
Results are shown for a–f Sham group, g–lmice with SCI, andm–rmice
with SCI treated with co-ultraPEALut. Double-stained sections at 24 h
post injury indicated that Beclin-1 expression increased in both neurons
and astrocytes respectively.Orange arrows indicate co-localizations (g–l)
and revealed a high co-localization between NeuN/Beclin1 and GFAP/
Beclin-1 double staining. Treatment with the co-ultraPEALut
reduced Beclin-1 expression (m–r). All images were digitalized at a
resolution of 8 bits into an array of 2048×2048 pixels
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play a central role in regulating the pathogenesis of acute and
chronic SCI [22]. Functional recovery after SCI is often poor
and, as yet, there are no nonsurgical therapies that have been
successfully translated for use in the clinic. Therefore, there is
a great need for drugs that will reduce post-traumatic,
inflammation-related spinal cord damage because it has been
reported that reducing inflammation decreases secondary de-
generation and the functional deficit after SCI. In a previous
study, we showed that co-ultraPEALut treatment (1 mg/kg)
exerted beneficial effects in ex vivo model using spinal cord
organotypic slice cultures and in in vivo model of spinal cord
compression injury in mice. Briefly, we found that co-
ultraPEALut had anti-inflammatory, antioxidant, and neuro-
protective properties [18].
Furthermore, recent studies demonstrated that another pos-
sible consequence of SCI is energy depletion, and this elicits
autophagy [15, 16, 23]. Autophagy is a cellular catabolic deg-
radation response to starvation or stress, whereby cellular pro-
teins, organelles, and cytoplasm are engulfed, digested, and
recycled to sustain cellular metabolism [9, 24]. Constitutive,
basal autophagy also has an important homeostatic function,
by maintaining protein and organelle quality control. Al-
though most evidence supports a role for autophagy in sus-
taining cell survival, paradoxically, cell death resulting from
progressive cellular consumption has been attributed to unre-
strained autophagy [25–27]. The mechanisms that regulate the
mutually opposed survival and death roles for autophagy are
still unknown. The most plausible explanation is that catabo-
lism through autophagy is predominantly survival-supporting,
but that an imbalance in cell metabolism, where autophagic
cellular consumption exceeds the cellular capacity for synthe-
sis, promotes cell death [28].
Therefore, the aim of the present study was to explore new
therapeutic approaches promoting survival of cells. In partic-
ular, we wanted to investigate whether the new compound co-
ultraPEALut (at the dose of 1 mg/kg) was able to modulate
autophagy promoting functional recovery after SCI.
In the first step, using H&E staining, we evaluated the
effect of co-ultraPEALut on spinal cord at the level of the
perilesional area at 24 h after injury. Histological analysis
showed that mice, after SCI, presented edema and alteration
of the white matter, while mice treated with co-ultraPEALut
showed an attenuation of acute inflammation and injury after
SCI.
In the second step, we studied the effects of this new com-
pound on autophagy markers after SCI. At first, we examined
the levels of proteins that promote autophagy such as Beclin-1
and MAP-LC3. Beclin-1 is a protein that participates in the
regulation of autophagy and has an important role in develop-
ment, tumorigenesis, and neurodegeneration [29]. Beclin-1
functions as a scaffold for the formation of the PI3K complex,
one of the first components recruited during the development
of autophagosomes. During autophagy initiation and
autophagosome formation, Beclin-1 binds microtubule-
Fig. 4 Co-localization of NeuN/LC3 and GFAP/LC3 after SCI. Results
are shown for (a–f) Sham group, (g–l) mice with SCI, and (m–r) mice
with SCI treated with co-ultraPEALut. Double-stained sections at 24 h
post-injury indicated that LC3 expression increased in both neurons and
astrocytes respectively.Orange arrows indicate co-localizations (g–l) and
revealed a high co-localization between NeuN/LC3 and GFAP/LC3
double staining. Treatment with the Co-ultraPEALut reduced Beclin-1
expression (m–r). All images were digitalized at a resolution of 8 bits
into an array of 2048×2048 pixels
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associated protein 1A/1B-light chain 3 I (LC3I) that is con-
verted to its membrane-bound form (LC3II), which then inter-
acts with the ubiquitin-binding protein p62/sequestosome 1
[30–32]. Since p62 accumulates when autophagy is inhibited
and decreased levels can be observed when autophagy is in-
duced, p62 may be used as a marker to study autophagic flux
[32]. In this study, we observed an increase of the expression
of Beclin-1, LC3, and p62 after SCI that dramatically de-
creased after treatment with co-ultraPEALut. Furthermore,
we wanted to assess whether Beclin-1 and MAP-LC3 were
expressed in specific cells. Therefore, the spinal cord sections
at 24 h after compression were double-stained for Beclin-1 or
MAP-LC3 and various cell type markers, such as NeuN for
neurons and GFAP for astrocytes. By immunofluorescence
staining, we observed a strong co-localization of Beclin-1
and LC3with Neun and GFAP. These results showed that after
SCI, the expression of these two proteins increases in neurons
and astrocytes, while treatment with co-ultraPEALut reduces
the levels of Beclin-1 and LC3 in both cell types.
Finally, we wanted to evaluate the effect of co-ultraPEALut
on Akt/mTOR/p70S6K pathway that in autophagy has been
considered a central regulatory pathway of the protein trans-
lation involved in regulating cell proliferation, growth, differ-
entiation, and survival [33, 34]. mTOR kinase is a master
regulator of autophagy directly suppressing autophagy. This
protein is a central signal integrator that functions as a check-
point with upstream Akt and downstream p70S6K being the
two most important mediators [8]. Therefore, using western
blot analysis, we detected mTOR expression and the phos-
phorylation of Akt after SCI. Our results indicated that p-
Akt and mTOR levels decreased significantly after SCI, while
co-ultraPEALut treatment increased expression of these pro-
teins. Moreover, p70S6k activity was suppressed in mice after
SCI, whereas the co-ultraPEALut treatment enhanced activa-
tion of p70S6K signaling. These data confirmed that the pro-
tective role of co-ultraPEALut is associated with inhibition of
excessive autophagy via Akt/mTOR/p70S6K signals and reg-
ulation of protein degradation.
Fig. 5 Effect of co-ultra PEALut about proteins inhibiting autophagy
after SCI. Western blot analysis for mTOR, p-Akt, and p70S6K showed
a decrease of levels of these proteins in SCI group compared to the Sham
group, whereas the treatment with co-ultraPEALut significantly increased
SCI-induced mTOR, p-Akt, and p70S6K expression (a, a1; b, b1; c, c1
respectively). The data are representative of at least three independent
experiments. a **p<0.01 vs Sham; #p<0.05 vs SCI. b **p<0.01 vs
Sham; ##p<0.01 vs SCI. c ***p<0.001 vs Sham; ##p<0.01 vs SCI
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We conclude that co-ultraPEALut treatment at the dose of
1 mg/kg is capable to improve neurobehavioral functions, and
reduce apoptotic cell death and neuroinflammation, improv-
ing tissue structure after SCI [18]. In addition, our results
suggest that SCI induces autophagic cell death at the lesion
site; therefore, co-ultraPEALut treatment inhibiting autophagy
in in vivo model of SCI has protective effect. In conclusion,
co-ultraPEALut could be considered as a possible therapeutic
target in an acute traumatic lesion like SCI.
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